BioCentury | Apr 1, 2013
Company News

Cytori gene/cell therapy news

...pathway rather than a 510(k) application. Cytori was seeking approval of its Celution 700 and StemSource...
BioCentury | Jan 19, 2009
Company News

Cytori, General Electric sales and marketing update

...18 months for use in translational medicine and stem cell banking in combination with Cytori's StemSource...
BioCentury | Oct 15, 2007
Clinical News

Celution System regulatory update

...tissue. Green Hospital Supply Inc. (Tokyo:3360, Osaka, Japan), which has Japanese rights to market CYTX's StemSource...
BioCentury | Aug 20, 2007
Company News

Cytori, Green Hospital Supply Inc. sales and marketing update

...Green Hospital received exclusive rights to market CYTX's StemSource cell bank in Japan. StemSource includes the...
BioCentury | Oct 14, 2002
Company News

MacroPore, StemSource deal

...the remaining outstanding shares of stem cell company StemSource for 1.4 million shares of XMP. StemSource...
...adult stem cell-based therapeutics to degenerative and chronic conditions. MacroPore Biosurgery Inc. (FSE:XMP), Frankfurt, Germany StemSource Inc....
Items per page:
1 - 5 of 5
BioCentury | Apr 1, 2013
Company News

Cytori gene/cell therapy news

...pathway rather than a 510(k) application. Cytori was seeking approval of its Celution 700 and StemSource...
BioCentury | Jan 19, 2009
Company News

Cytori, General Electric sales and marketing update

...18 months for use in translational medicine and stem cell banking in combination with Cytori's StemSource...
BioCentury | Oct 15, 2007
Clinical News

Celution System regulatory update

...tissue. Green Hospital Supply Inc. (Tokyo:3360, Osaka, Japan), which has Japanese rights to market CYTX's StemSource...
BioCentury | Aug 20, 2007
Company News

Cytori, Green Hospital Supply Inc. sales and marketing update

...Green Hospital received exclusive rights to market CYTX's StemSource cell bank in Japan. StemSource includes the...
BioCentury | Oct 14, 2002
Company News

MacroPore, StemSource deal

...the remaining outstanding shares of stem cell company StemSource for 1.4 million shares of XMP. StemSource...
...adult stem cell-based therapeutics to degenerative and chronic conditions. MacroPore Biosurgery Inc. (FSE:XMP), Frankfurt, Germany StemSource Inc....
Items per page:
1 - 5 of 5